Article
Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.
JCI insight - 24 Jan 2023
Stölzel Friedrich, Fordham Sarah E, Nandana Devi, Lin Wei-Yu, Blair Helen, Elstob Claire, Bell Hayden L, Mohr Brigitte, Ruhnke Leo, Kunadt Desiree, Dill Claudia, Allsop Daniel, Piddock Rachel, Soura Emmanouela-Niki, Park Catherine, Fadly Mohd, Rahman Thahira, Alharbi Abrar, Wobus Manja, Altmann Heidi, Röllig Christoph, Wagenführ Lisa, Jones Gail L, Menne Tobias, Jackson Graham H, Marr Helen J, Fitzgibbon Jude, Onel Kenan, Meggendorfer Manja, Robinson Amber, Bziuk Zuzanna, Bowes Emily, Heidenreich Olaf, Haferlach Torsten, Villar Sara, Ariceta Beñat, Diaz Rosa Ayala, Altschuler Steven J, Wu Lani F, Prosper Felipe, Montesinos Pau, Martinez-Lopez Joaquin, Bornhäuser Martin, Allan James M
Abstract excerpt
Precision medicine can significantly improve outcomes for patients with cancer, but implementation requires comprehensive characterization of tumor cells to identify therapeutically exploitable vulnerabilities. Here, we describe somatic biallelic TET2 mutations in an elderly patient with acute myeloid leukemia (AML) that was chemoresistant to anthracycline and cytarabine but acutely sensitive to 5'-azacitidine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.